1
|
Inhibition of nuclear factor kappa B as a mechanism of Danshensu during Toll-like receptor 2-triggered inflammation in macrophages. Int Immunopharmacol 2020; 83:106419. [PMID: 32200153 DOI: 10.1016/j.intimp.2020.106419] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 03/13/2020] [Accepted: 03/13/2020] [Indexed: 01/08/2023]
Abstract
Danshensu (DSS) is a water-soluble phenolic compound in Danshen (Salvia Miltiorrhiza Radix et Rhizoma). Although various pharmacological activities have been recognized, little is known regarding its anti-inflammatory effect and related molecular mode of action. In the current study, bone marrow-derived macrophages (BMMs) were activated by a Toll-like receptor 2 (TLR2) agonist Pam3CSK4 with or without DSS intervention. Production of pro-inflammatory cytokines interleukin-6 (IL-6) and interleukin-12 (IL-12) was detected by both enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (RT-qPCR). Activation of signaling pathways involving nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs) was assessed by Western blot. Additionally, RNA sequencing (RNA-seq) combined with bioinformatics analyses was applied to investigate the molecular mechanisms of DSS. Emphasis was placed on the construction of the protein-protein interaction (PPI) network and transcription factor (TF) enrichment analysis of data including co-regulated differentially expressed genes (DEGs) in the Pam3CSK4 vs. control and DSS vs. Pam3CSK4 groups. The RT-qPCR and ELISA results showed that DSS effectively inhibited the expressions of IL-6 and IL-12, indicating a significant anti-inflammatory effect. Western blot verified that DSS suppressed the phosphorylation of p65, which was in accordance with the results of the TF enrichment analysis. Additionally, the PPI network analysis showed several key molecules, including lactoferrin (Ltf), CC-chemokine receptor 7 (Ccr7), interferon-gamma (IFN-γ) and C-X-C motif chemokine ligand 9 (Cxcl9), to be regulatory genes that responded to DSS treatment. Overall, our study revealed that DSS has a pronounced anti-inflammatory effect involving TLR2 and macrophages through the NF-κB signaling pathway, which supports the novel application of DSS in the treatment of relevant diseases including atherosclerosis and ischemic or ischemic/perfusion injury of the heart and brain.
Collapse
|
2
|
Nuzzo PV, Buzzatti G, Ricci F, Rubagotti A, Argellati F, Zinoli L, Boccardo F. Periostin: a novel prognostic and therapeutic target for genitourinary cancer? Clin Genitourin Cancer 2014; 12:301-11. [PMID: 24656869 DOI: 10.1016/j.clgc.2014.02.005] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Revised: 01/29/2014] [Accepted: 02/12/2014] [Indexed: 01/21/2023]
Abstract
Many of the cellular abnormalities present in solid tumors are structural in nature and involve the proteins of the extracellular matrix (ECM). Periostin is a protein produced and secreted by the fibroblasts as a component of the ECM where it is involved in regulating intercellular adhesion. The expression of periostin has an important physiological role during embryogenesis and growth, namely at the level of bone, dental, and cardiac tissues. Many studies indicate that periostin plays an important role for tumor progression in various types of cancer, such as colon, lung, head and neck, breast, ovarian, and prostate. To the best of our knowledge, a limited number of studies have investigated periostin expression in urogenital cancer, such as prostate, bladder, penile, and renal cancer, and no studies were performed in testis cancer. In this review article, we summarize the most recent knowledge of periostin, its genetic and protein structure, and the role of the different isoforms identified and sequenced so far. In particular, we focus our attention on the role of this protein in genitourinary tumors, trying to emphasize the role not only as a possible prognostic marker, but also as a possible target for the development of future anticancer therapies.
Collapse
Affiliation(s)
- Pier Vitale Nuzzo
- Academic Unit of Medical Oncology (Medical Oncology B), University of Genoa, School of Medicine, Genoa, Italy; Department of Internal Medicine, University of Genoa, School of Medicine, Genoa, Italy
| | - Giulia Buzzatti
- Academic Unit of Medical Oncology (Medical Oncology B), University of Genoa, School of Medicine, Genoa, Italy; Department of Internal Medicine, University of Genoa, School of Medicine, Genoa, Italy
| | - Francesco Ricci
- Academic Unit of Medical Oncology (Medical Oncology B), University of Genoa, School of Medicine, Genoa, Italy; IRCCS San Martino University Hospital - IST National Cancer Research Institute, Genoa, Italy
| | - Alessandra Rubagotti
- Academic Unit of Medical Oncology (Medical Oncology B), University of Genoa, School of Medicine, Genoa, Italy; Department of Internal Medicine, University of Genoa, School of Medicine, Genoa, Italy; IRCCS San Martino University Hospital - IST National Cancer Research Institute, Genoa, Italy
| | - Francesca Argellati
- Academic Unit of Medical Oncology (Medical Oncology B), University of Genoa, School of Medicine, Genoa, Italy; IRCCS San Martino University Hospital - IST National Cancer Research Institute, Genoa, Italy
| | - Linda Zinoli
- Academic Unit of Medical Oncology (Medical Oncology B), University of Genoa, School of Medicine, Genoa, Italy; Department of Internal Medicine, University of Genoa, School of Medicine, Genoa, Italy; IRCCS San Martino University Hospital - IST National Cancer Research Institute, Genoa, Italy
| | - Francesco Boccardo
- Academic Unit of Medical Oncology (Medical Oncology B), University of Genoa, School of Medicine, Genoa, Italy; Department of Internal Medicine, University of Genoa, School of Medicine, Genoa, Italy; IRCCS San Martino University Hospital - IST National Cancer Research Institute, Genoa, Italy.
| |
Collapse
|
3
|
Abstract
Despite significant advances in surgery, radiotherapy and chemotherapy to treat prostate cancer (CaP), many patients die of secondary disease (metastases). Current therapeutic approaches are limited, and there is no cure for metastatic castration-resistant prostate cancer (CRPC). Epithelial cell adhesion molecule (EpCAM, also known as CD326) is a transmembrane glycoprotein that is highly expressed in rapidly proliferating carcinomas and plays an important role in the prevention of cell-cell adhesion, cell signalling, migration, proliferation and differentiation. Stably and highly expressed EpCAM has been found in primary CaP tissues, effusions and CaP metastases, making it an ideal candidate of tumour-associated antigen to detect metastasis of CaP cells in the circulation as well as a promising therapeutic target to control metastatic CRPC disease. In this review, we discuss the implications of the newly identified roles of EpCAM in terms of its diagnostic and metastatic relevance to CaP. We also summarize EpCAM expression in human CaP and EpCAM-mediated signalling pathways in cancer metastasis. Finally, emerging and innovative approaches to the management of the disease and expanding potential therapeutic applications of EpCAM for targeted strategies in future CaP therapy will be explored.
Collapse
|